Prescribing Information
PATIENT SITE

DARZALEX FASPRO® DOSING & ADMINISTRATION GUIDE
DARZALEX® DOSING & ADMINISTRATION GUIDE
GET IN TOUCH

INDICATIONS AND DOSING
- Newly Diagnosed
  - DRd
  - DVMP
  - DVTd
- Relapsed or Refractory

NCCN RECOMMENDATIONS

CLINICAL TRIALS

DARZALEX FASPRO^®: COLUMBA

ADDITIONAL TRIALS

PRACTICE SUPPORT

PATIENT SUPPORT

MECHANISM OF ACTION

FOR APPs AND NURSES

PRESCRIBING INFORMATION

DARZALEX FASPRO^® Prescribing Information

DARZALEX FASPRO^® la información de prescripción

DARZALEX^® Prescribing Information

Important Safety Information

DARZALEX FASPRO^® Important Safety Information

DARZALEX^® Important Safety Information

Email Medical Information Center

Search Janssen MD

Dosing & Administration Guide

DARZALEX FASPRO^® Dosing & Administration Guide

DARZALEX^® Dosing & Administration Guide

PATIENT SITE
JANSSEN MYELOMA TREATMENTS
For US Healthcare Professionals

Site Map

Home
Site Map

Product Use
Clinical Trials
Resources
For APPs and Nurses

Failed to load

Medical Information Center

|

Site Map

© JANSSEN BIOTECH, INC. 2023

This site is published by JANSSEN BIOTECH, INC., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. JANSSEN BIOTECH, INC., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Last updated May 2023 | cp-233680v2

No footer links content fetched